Allergy to illicit drugs and narcotics

Clinical and Experimental Allergy

Volumn 44, Issue 3, 2014, Pages 307-318

  Swerts, S ^a   Van Gasse, A ^a   Leysen, J ^a   Faber, M ^a   Sabato, V ^a   Bridts, C H ^a   Jorens, P G ^a   De Clerck, L S ^a   Ebo, D G ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG HYPERSENSITIVITY; HUMANS; IMMUNOGLOBULIN E; NARCOTICS; STREET DRUGS;

EID: 84894225714     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12177     Document Type: Review

References (127)

1. UNODC, World Drug Report 2011 (United Nations Publication, Sales No. E.11.XI.10). ISBN: 978-92-1-148262-1, e-ISBN: 978-92-1-054919-6.
2. Degenhardt I, Hall W. Extent of illicit drug use and dependence, and their contribution on the global burden of disease. Lancet 2012; 739:55-70.
3. Spiewak R, Gora A, Dutkiewicz J. Work-related skin symptoms and type I allergy among eastern-Polish farmers growing hops and other crops. Ann Agric Environ Med 2001; 8:51-6.
4. Williams C, Thompstone J, Wilkinson M. Work-related contact urticaria to Cannabis sativa. Contact Dermatitis 2008; 58:62-3.
5. Herzinger T, Schopf P, Przybilla B, Rueff F. IgE-mediated hypersensitivity reactions to cannabis in laboratory personnel. Int Arch Allergy Immunol 2011; 156:423-6.
6. Liskow B, Liss JL, Parker CW. Allergy to marihuana. Ann Intern Med 1971; 75:571-3.
7. Anibarro B, Fontela JL. Allergy to marihuana. Allergy 1996; 51:200-1.
8. Perez JA Jr. Allergic reaction associated with intravenous marijuana use. J Emerg Med 2000; 18:260-1.
9. Stadtmauer G, Beyer K, Bardina L, Sicherer SH. Anaphylaxis to ingestion of hempseed (Cannabis sativa). J Allergy Clin Immunol 2003; 112:216-7.
10. Majmudar V, Azam NA, Finch T. Contact urticaria to Cannabis sativa. Contact Dermatitis 2006; 54:127.
11. Gamboa P, Sanchez-Monge R, Sanz ML, Palacin A, Salcedo G, Diaz-Perales A. Sensitization to Cannabis sativa caused by a novel allergenic lipid transfer protein, Can s 3. J Allergy Clin Immunol 2007; 120:1459-60.
12. Stockli SS, Bircher AJ. Generalized pruritus in a patient sensitized to tobacco and cannabis. J Dtsch Dermatol Ges 2007; 5:303-4.
13. de Larramendi CH, Carnes J, Garcia-Abujeta JL et al. Sensitization and allergy to Cannabis sativa leaves in a population of tomato (Lycopersicon esculentum)-sensitized patients. Int Arch Allergy Immunol 2008; 146:195-202.
14. Armentia A, Castrodeza J, Ruiz-Munoz P et al. Allergic hypersensitivity to cannabis in patients with allergy and illicit drug users. Allergol Immunopathol (Madr) 2011; 39:271-9.
15. Tessmer A, Berlin N, Sussman G, Leader N, Chung EC, Beezhold D. Hypersensitivity reactions to marijuana. Ann Allergy Asthma Immunol 2012; 108:282-4.
16. Freeman GL. Allergic skin test reactivity to marijuana in the Southwest. West J Med 1983; 138:829-31.
17. Stokes JR, Hartel R, Ford LB, Casale TB. Cannabis (hemp) positive skin tests and respiratory symptoms. Ann Allergy Asthma Immunol 2000; 85:238-40.
18. Torre FD, Limonta A, Molinari A, Masala E, Vercelloni S, Torre ED. Cannabaceae pollen in the atmosphere of Brianza, Northen Italy. Eur Ann Allergy Clin Immunol 2007; 39:9-11.
19. Mayoral M, Calderon H, Cano R, Lombardero M. Allergic rhinoconjunctivitis caused by Cannabis sativa pollen. J Investig Allergol Clin Immunol 2008; 18:73-4.
20. Singh AB, Shahi S. Aeroallergens in clinical practice of allergy in India- ARIA Asia Pacific Workshop report. Asian Pac J Allergy Immunol 2008; 26:245-56.
21. Prasad R, Verma SK, Dua R, Kant S, Kushwaha RA, Agarwal SP. A study of skin sensitivity to various allergens by skin prick test in patients of nasobronchial allergy. Lung India 2009; 26:70-3.
22. Metz-Favre C, Pauli G, Bessot JC, De BF. Molecular allergology in practice: an unusual case of LTP allergy. Eur Ann Allergy Clin Immunol 2011; 43:193-5.
23. Ebo DG, Swerts S, Sabato V, Hagendorens MM, Jorens P, De Clerck LS. New food allergies in a European non-Mediterranean region: is Cannabis sativa to blame? Int Arch Allergy Immunol 2013; 161:220-8.
24. Jegou S, Douliez JP, Molle D, Boivin P, Marion D. Purification and structural characterization of LTP1 polypeptides from beer. J Agric Food Chem 2000; 48:5023-9.
25. Asero R, Mistrello G, Roncarolo D, Amato S, van RR. A case of allergy to beer showing cross-reactivity between lipid transfer proteins. Ann Allergy Asthma Immunol 2001; 87:65-7.
26. Carnes J, de Larramendi CH, Ferrer A et al. Recently introduced foods as new allergenic sources: sensitisation to Goji berries (Lycium barbarum). Food Chem 2013; 137:130-5.
27. Beezhold DH, Hickey VL, Kostyal DA et al. Lipid transfer protein from Hevea brasiliensis (Hev b 12), a cross-reactive latex protein. Ann Allergy Asthma Immunol 2003; 90:439-45.
28. Rihs HP, Rueff F, Lundberg M et al. Relevance of the recombinant lipid transfer protein of Hevea brasiliensis: IgE-binding reactivity in fruit-allergic adults. Ann Allergy Asthma Immunol 2006; 97:643-9.
29. Vidal C, Fuente R, Iglesias A, Saez A. Bronchial asthma due to Cannabis sativa seed. Allergy 1991; 46:647-9.
30. Ebo DG, Hagendorens MM, Bridts CH, De Clerck LS, Stevens WJ. Sensitization to cross-reactive carbohydrate determinants and the ubiquitous protein profilin: mimickers of allergy. Clin Exp Allergy 2004; 34:137-44.
31. Andersen MB, Hall S, Dragsted LO. Identification of european allergy patterns to the allergen families PR-10, LTP, and profilin from Rosaceae fruits. Clin Rev Allergy Immunol 2011; 41:4-19.
32. Baldo BA, Pham NH. Histamine-releasing and allergenic properties of opioid analgesic drugs: resolving the two. Anaesth Intensive Care 2012; 40:216-35.
33. Glover R, Trottier L. Pharmacy involvement in the evaluation of drug allergies. Can J Hosp Pharm 1977; 30:38-44.
34. Tripp DM, Brown GR. Pharmacist assessment of drug allergies. Am J Hosp Pharm 1993; 50:95-8.
35. Bouwmeester MC, Laberge N, Bussieres JF, Lebel D, Bailey B, Harel F. Program to remove incorrect allergy documentation in pediatrics medical records. Am J Health Syst Pharm 2001; 58:1722-7.
36. Weingart SN, Toth M, Sands DS. Physicians' decisions to override computerized drug alerts in primary care. Arch Intern Med 2003; 163:2625-31.
37. Dong SW, Mertes PM, Pepitain N, Hasdenteufel F, Malinovsky M. Hypersensitivity reactions during anesthesia. Results from the ninth French survey (2005-2007). Minerva Anestesiol 2012; 78:868-78.
38. Harle DG, Baldo BA, Coroneos NJ, Fisher MM. Anaphylaxis following administration of papaveretum. Case report: implication of IgE antibodies that react with morphine and codeine, and identification of an allergenic determinant. Anesthesiology 1989; 71:489-94.
39. Fahmy NR. Hemodynamics, plasma histamine, and catecholamine concentrations during an anaphylactoid reaction to morphine. Anesthesiology 1981; 55:329-31.
40. Rossi R, Dick W. Anaphylactoid reaction to the intravenous injection of morphine hydrochloride. Anaesthesist 1982; 31:463-5.
41. Stefanutto TB, Wright PMC. Anaphylaxis precipitated by intravenous morphine sulphate. SAJAA 2005; 1:36-7.
42. Stefanutto EC, Marshall AG, Garrett CP. Adverse reactions to intravenous codeine phosphate in children. A report of three cases. Anaesthesia 1983; 38:40-3.
43. Hunskaar S, Dragsund S. Scarlatiniform rash and urticaria due to codeine. Ann Allergy 1985; 54:240-1.
44. Vidal C, Perez-Leiros P, Bugarin R, Armisen M. Fever and urticaria to codeine. Allergy 2000; 55:416-7.
45. Nasser SM, Ewan PW. Opiate-sensitivity: clinical characteristics and the role of skin prick testing. Clin Exp Allergy 2001; 31:1014-20.
46. Prieto-Lastra L, Iglesias-Cadarso A, Reano-Martos MM, Perez-Pimiento A, Rodriguez-Cabreros MI, Garcia-Cubero A. Pharmacological stimuli in asthma/urticaria. Allergol Immunopathol (Madr) 2006; 34:224-7.
47. Anibarro B, Vila C, Seoane FJ. Urticaria induced by meperidine allergy. Allergy 2000; 55:305-6.
48. Leysen J, Sabato V, Faber M et al. IgE-mediated allergy to pholcodine and cross-reactivity to neuromuscular blocking agents: lessons from flow cytometry. Cytometry B Clin Cytom 2013; 84:65-70.
49. Florvaag E, Johansson SG, Oman H et al. Prevalence of IgE antibodies to morphine. Relation to the high and low incidences of NMBA anaphylaxis in Norway and Sweden, respectively. Acta Anaesthesiol Scand 2005; 49:437-44.
50. Ebo DG, Venemalm L, Bridts CH et al. Immunoglobulin E antibodies to rocuronium: a new diagnostic tool. Anesthesiology 2007; 107:253-9.
51. Armentia A, Ruiz-Munoz P, Quesada JM et al. Clinical value of morphine, pholcodine and poppy seed IgE assays in drug-abusers and allergic people. Allergol Immunopathol (Madr) 2013; 41:37-44.
52. Ebertz JM, Hermens JM, McMillan JC, Uno H, Hirshman C, Hanifin JM. Functional differences between human cutaneous mast cells and basophils: a comparison of morphine-induced histamine release. Agents Actions 1986; 18:455-62.
53. Stellato C, Cirillo R, de PA et al. Human basophil/mast cell releasability. IX. Heterogeneity of the effects of opioids on mediator release. Anesthesiology 1992; 77:932-40.
54. Withington DE, Patrick JA, Reynolds F. Histamine release by morphine and diamorphine in man. Anaesthesia 1993; 48:26-9.
55. Codreanu F, Morisset M, Kanny G, Moneret-Vautrin DA. Allergy to pholcodine: first case documented by oral challenge. Allergy 2005; 60:544-5.
56. Florvaag E, Johansson SG, Oman H, Harboe T, Nopp A. Pholcodine stimulates a dramatic increase of IgE in IgE-sensitized individuals. A pilot study. Allergy 2006; 61:49-55.
57. Harboe T, Johansson SG, Florvaag E, Oman H. Pholcodine exposure raises serum IgE in patients with previous anaphylaxis to neuromuscular blocking agents. Allergy 2007; 62:1445-50.
58. Baldo BA, Fisher MM. Substituted ammonium ions as allergenic determinants in drug allergy. Nature 1983; 306:262-4.
59. Mushlin N, Vahid B, Roberts R. Use of naloxone in hydromorphone-induced anaphylactoid reaction. South Med J 2007; 100:611.
60. Rook EJ, van Zanten AP, van den Brink W, van Ree JM, Beijnen JH. Mast cell mediator tryptase levels after inhalation or intravenous administration of high doses pharmaceutically prepared heroin. Drug Alcohol Depend 2006; 85:185-90.
61. Weidman AI, Fellner MJ. Cutaneous manifestations of heroin and other addictive drugs. Study and analysis. N Y State J Med 1971; 71:2643-6.
62. Del Giudice P. Cutaneous complications of intravenous drug abuse. Br J Dermatol 2004; 150:1-10.
63. Shaikh WA. Allergy to heroin. Allergy 1990; 45:555-6.
64. Moneret-Vautrin DA, Renaudin JM, Kanny G. Allergie à l'héroine chez un toxicomane. Rev Fr Allergol 1997; 37:398.
65. Gooch I, Gwinnutt C. Anaphylaxis to intrathecal diamorphine. Resuscitation 2006; 70:470-3.
66. Hogen Esch AJ, van der Heide S, van den Brink W, van Ree JM, Bruynzeel DP, Coenraads PJ. Contact allergy and respiratory/mucosal complaints from heroin (diacetylmorphine). Contact Dermatitis 2006; 54:42-9.
67. Whale CI, Molyneux AW, Ward MJ. Inhaled heroin causing a life-threatening asthma exacerbation and marked peripheral eosinophilia. Br J Hosp Med (Lond) 2007; 68:332-3.
68. Elia D, Marinou A, Chetta A. Life-threatening asthma after heroin inhalation. A case report and a review of the literature. Acta Biomed 2010; 81:63-7.
69. Edston E, van Hage-Hamsten M. Anaphylactoid shock: a common cause of death in heroin addicts? Allergy 1997; 52:950-4.
70. Flacke JW, Flacke WE, Bloor BC, Van Etten AP, Kripke BJ. Histamine release by four narcotics: a double-blind study in humans. Anesth Analg 1987; 66:723-30.
71. Levy JH, Brister NW, Shearin A et al. Wheal and flare responses to opioids in humans. Anesthesiology 1989; 70:756-60.
72. Blunk JA, Schmelz M, Zeck S, Skov P, Likar R, Koppert W. Opioid-induced mast cell activation and vascular responses is not mediated by mu-opioid receptors: an in vivo microdialysis study in human skin. Anesth Analg 2004; 98:364-70.
73. Butler EB. A case of hypersensitivity to pethidine in a woman in labour. Br Med J 1951; 2:715-6.
74. Levy JH, Rockoff MA. Anaphylaxis to meperidine. Anesth Analg 1982; 61:301-3.
75. Marone G, Stellato C, Mastronardi P, Mazzarella B. Mechanisms of activation of human mast cells and basophils by general anesthetic drugs. Ann Fr Anesth Reanim 1993; 12:116-25.
76. Hayden J Jr, Scott E. A significant histamine response with fentanyl: report of a case. Anesth Prog 1974; 21:84.
77. Pevny I, Danhauser I. Anaphylactic shock during general anaesthesia due to fentanyl and alloferin in a patient with positive skin test (author's transl). Anaesthesist 1981; 30:400-4.
78. Bennett MJ, Anderson LK, McMillan JC, Ebertz JM, Hanifin JM, Hirshman CA. Anaphylactic reaction during anaesthesia associated with positive intradermal skin test to fentanyl. Can Anaesth Soc J 1986; 33:75-8.
79. Chudnofsky CR, Wright SW, Dronen SC, Borron SW, Wright MB. The safety of fentanyl use in the emergency department. Ann Emerg Med 1989; 18:635-9.
80. Fukuda T, Dohi S. Anaphylactic reaction to fentanyl or preservative. Can Anaesth Soc J 1986; 33:826-7.
81. Cummings KC III, Arnaut K. Case report: fentanyl-associated intraoperative anaphylaxis with pulmonary edema. Can J Anaesth 2007; 54:301-6.
82. Milojevic I, Simic D, Markovic M, Atanaskovic-Markovic M, Milosevic K, Trifunovic B. Anaphylactic reaction during general anaesthesia associated with positive skin test to fentanyl. Anaesth Intensive Care 2009; 37:502-3.
83. Belso N, Kui R, Szegesdi I et al. Propofol and fentanyl induced perioperative anaphylaxis. Br J Anaesth 2011; 106:283-4.
84. Mertes PM, Alla F, Trechot P, Auroy Y, Jougla E. Anaphylaxis during anesthesia in France: an 8-year national survey. J Allergy Clin Immunol 2011; 128:366-73.
85. Baldo BA, Pham NH, Zhao Z. Chemistry of drug allergenicity. Curr Opin Allergy Clin Immunol 2001; 1:327-35.
86. Lewis KS, Han NH. Tramadol: a new centrally acting analgesic. Am J Health Syst Pharm 1997; 54:643-52.
87. Shipton EA. Tramadol-present and future. Anaesth Intensive Care 2000; 28:363-74.
88. Barth H, Giertz H, Schmal A, Lorenz W. Anaphylactoid reactions and histamine release do not occur after application of the opioid tramadol. Agents Actions 1987; 20:310-3.
89. Tedeschi A, Lorini M, Suli C, Cugno M. Detection of serum histamine-releasing factors in a patient with idiopathic anaphylaxis and multiple drug allergy syndrome. J Investig Allergol Clin Immunol 2007; 17:122-5.
90. Asero R. Chronic urticaria with multiple NSAID intolerance: is tramadol always a safe alternative analgesic? J Investig Allergol Clin Immunol 2003; 13:56-9.
91. Hallberg P, Brenning G. Angioedema induced by tramadol-a potentially life-threatening condition. Eur J Clin Pharmacol 2005; 60:901-3.
92. Grassmann C. An unusual adverse reaction to tramadol. Anaesthesia 2008; 63:442.
93. Uehlinger C, Hauser C. Allergic reactions from injectable methadone. Am J Psychiatry 1999; 156:973.
94. Singh YN. Kava: an overview. J Ethnopharmacol 1992; 37:13-45.
95. Shimoda LM, Park C, Stokes AJ, Gomes HH, Turner H. Pacific Island 'Awa (Kava) extracts, but not isolated kavalactones, promote proinflammatory responses in model mast cells. Phytother Res 2012; 26:1934-41.
96. Suss R, Lehmann P. Hematogenous contact eczema cause by phytogenic drugs exemplified by kava root extract. Hautarzt 1996; 47:459-61.
97. Ernst E. Adverse effects of herbal drugs in dermatology. Br J Dermatol 2000; 143:923-9.
98. Schmidt P, Boehncke WH. Delayed-type hypersensitivity reaction to kava-kava extract. Contact Dermatitis 2000; 42:363-4.
99. Grace R. Kava-induced urticaria. J Am Acad Dermatol 2005; 53:906.
100. Jappe U, Franke I, Reinhold D, Gollnick HP. Sebotropic drug reaction resulting from kava-kava extract therapy: a new entity? J Am Acad Dermatol 1998; 38:104-6.
101. Plowman T. The origin, evolution, and diffusion of Coca, Erythroxylum spp, in South and Central America. In: Stone D, ed. Pre-Columbian Plant Migration; in Papers of the Peabody Museum of Archeology and Ethnology. Cambridge, MA: Harvard University, 1984:125-63.
102. Casale JF, Klein RFX. Illicit production of cocaine. Forensic Sci Rev 1993; 5:95-107.
103. Dinis-Oliveira RJ, Carvalho F, Duarte JA, Proenca JB, Santos A, Magalhaes T. Clinical and forensic signs related to cocaine abuse. Curr Drug Abuse Rev 2012; 5:64-83.
104. Castro-Villamor MA, de las HP, Armentia A, Duenas-Laita A. Cocaine-induced severe angioedema and urticaria. Ann Emerg Med 1999; 34:296-7.
105. Hidalgo Mora JJ, Gimenez de LE, Sempere VE, Feliu SM. Uvular angioedema after intranasal cocaine consumption. Med Clin (Barc) 2002; 119:438-9.
106. Kestler A, Keyes L. Images in clinical medicine. Uvular angioedema (Quincke's disease). N Engl J Med 2003; 349:867.
107. Kinsey CM, Howell M. A 27-year-old woman with a swollen uvula, chest pain, and elevated creatinine phosphokinase levels. Chest 2008; 133:809-11.
108. Welling A. Enlarged uvula (Quincke's Oedema)-a side effect of inhaled cocaine?-A case study and review of the literature. Int Emerg Nurs 2008; 16:207-10.
109. Milroy CM, Clark JC, Forrest AR. Pathology of deaths associated with "ecstasy" and "eve" misuse. J Clin Pathol 1996; 49:149-53.
110. Kalant H. The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. CMAJ 2001; 165:917-28.
111. Milroy CM. "Ecstasy" associated deaths: what is a fatal concentration? Analysis of a case series. Forensic Sci Med Pathol 2011; 7:248-52.
112. Sauvageau A. Death from a possible anaphylactic reaction to ecstasy. Clin Toxicol (Phila) 2008; 46:156.
113. Gomez-Fernandez C, Feito RM, Casado VB, Herranz PP, Beato-Merino M, Casado JM. Facial eruption related to snorting Ecstasy. Eur J Dermatol 2010; 20:853-4.
114. Widler P, Mathys K, Brenneisen R, Kalix P, Fisch HU. Pharmacodynamics and pharmacokinetics of khat: a controlled study. Clin Pharmacol Ther 1994; 55:556-62.
115. Marker P, Krogdahl A. Plasma cell gingivitis apparently related to the use of khat: report of a case. Br Dent J 2002; 192:311-3.
116. Shibata H, Nabe T, Yamamura H, Kohno S. l-Ephedrine is a major constituent of Mao-Bushi-Saishin-To, one of the formulas of Chinese medicine, which shows immediate inhibition after oral administration of passive cutaneous anaphylaxis in rats. Inflamm Res 2000; 49:398-403.
117. Schulman S. Addressing the potential risks associated with ephedra use: a review of recent efforts. Public Health Rep 2003; 118:487-92.
118. Zaacks SM, Klein L, Tan CD, Rodriguez ER, Leikin JB. Hypersensitivity myocarditis associated with ephedra use. J Toxicol Clin Toxicol 1999; 37:485-9.
119. Kurt TL. Hypersensitivity myocarditis with ephedra use. J Toxicol Clin Toxicol 2000; 38:351.
120. Haas DA, Harper DG. Ketamine: a review of its pharmacologic properties and use in ambulatory anesthesia. Anesth Prog 1992; 39:61-8.
121. Karayan J, Lacoste L, Breuil K. Allergy to ketamine. Ann Fr Anesth Reanim 1990; 9:396-7.
122. Boynes SG, Lemak AL, Skradski DM, Cuddy MA. An allergic reaction following intramuscular administration of ketamine and midazolam. J Clin Pediatr Dent 2006; 31:77-9.
123. Hagau N, Bologa RO, Indrei CL, Longrois D, Dirzu DS, Gherman-Ionica N. Maximum non-reactive concentration of midazolam and ketamine for skin testing study in non-allergic healthy volunteers. Anaesth Intensive Care 2010; 38:513-8.
124. Krol CG, Janssen MJ. Unusual use of nutmeg. Ned Tijdschr Geneeskd 2010; 154:A2214.
125. Pastrana DJ, Beunza Nuin JJ, Ramirez MS, Orduna MJ. Nutmeg poisoning. Med Clin (Barc) 2008; 131:639.
126. Sastre J, Olmo M, Novalvos A, Ibanez D, Lahoz C. Occupational asthma due to different spices. Allergy 1996; 51:117-20.
127. Chen JL, Bahna SL. Spice allergy. Ann Allergy Asthma Immunol 2011; 107:191-9.